GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TetraLogic Pharmaceuticals Corp (OTCPK:TLOG) » Definitions » Long-Term Debt

TetraLogic Pharmaceuticals (TetraLogic Pharmaceuticals) Long-Term Debt : $30.81 Mil (As of Sep. 2016)


View and export this data going back to 2013. Start your Free Trial

What is TetraLogic Pharmaceuticals Long-Term Debt?

TetraLogic Pharmaceuticals's Long-Term Debt for the quarter that ended in Sep. 2016 was $30.81 Mil.

TetraLogic Pharmaceuticals's quarterly Long-Term Debt increased from Mar. 2016 ($29.08 Mil) to Jun. 2016 ($29.93 Mil) and increased from Jun. 2016 ($29.93 Mil) to Sep. 2016 ($30.81 Mil).

TetraLogic Pharmaceuticals's annual Long-Term Debt increased from Dec. 2013 ($0.00 Mil) to Dec. 2014 ($27.30 Mil) and increased from Dec. 2014 ($27.30 Mil) to Dec. 2015 ($28.28 Mil).


TetraLogic Pharmaceuticals Long-Term Debt Historical Data

The historical data trend for TetraLogic Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TetraLogic Pharmaceuticals Long-Term Debt Chart

TetraLogic Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15
Long-Term Debt
- 4.76 - 27.30 28.28

TetraLogic Pharmaceuticals Quarterly Data
Dec11 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.81 28.28 29.08 29.93 30.81

TetraLogic Pharmaceuticals  (OTCPK:TLOG) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.


TetraLogic Pharmaceuticals Long-Term Debt Related Terms

Thank you for viewing the detailed overview of TetraLogic Pharmaceuticals's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


TetraLogic Pharmaceuticals (TetraLogic Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
343 Phoenixville Pike, Malvern, PA, USA, 19355
TetraLogic Pharmaceuticals Corp is a biopharmaceutical company. The company is engaged in developing novel small molecule therapeutics in oncology.
Executives
Hudson Bay Capital Management Lp other: See Remarks 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Lazard Asset Management Llc other: See Remarks 30 ROCKEFELLER PLZ, 56TH FL., NEW YORK NY 10112
Nomura Holdings Inc other: See Remarks 1-13-1 NIHONBASHI, CHUO-KU, TOKYO M0 103-8645
Whitebox Multi-strategy Partners Lp other: See Remarks 3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Pandora Select Partners, L.p. other: See Remarks 3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Whitebox General Partner Llc other: See Remarks 3033 EXCELSIOR BLVD., SUITE 300, MINNEAPOLIS MN 55416
Highbridge Capital Management Llc other: See Remarks 277 PARK AVE, 23RD FLOOR, NEW YORK NY 10172
Sander Gerber other: See Remarks C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Whitebox Concentrated Convertible Arbitrage Partners, L.p. other: See Remarks 3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Whitebox Advisors Llc other: See Remarks 3033 EXCELSIOR BLVD., SUITE 500, MINNEAPOLIS MN 55416
Patrick Hutchison officer: CFO & Treasurer C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803
Clarus Ventures Ii, Llc 10 percent owner 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Clarus Lifesciences Ii, L.p. 10 percent owner 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Clarus Ventures Ii Gp, L.p. 10 percent owner 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Nicholas Simon 10 percent owner 101 MAIN STREET SUITE 1210, CAMBRIDGE MA 02142

TetraLogic Pharmaceuticals (TetraLogic Pharmaceuticals) Headlines

No Headlines